Back to Journals » Cancer Management and Research » Volume 12

Gene Therapy with Cytosine Deaminase and Endostatin Fusion Gene Mediated by Endothelial Progenitor Cells in Hepatomas

Authors Zhang YL, Zhou TY, Ai J, Chen SQ, Chen F, Nie CH, Chen XH, Zhou GH, Wang HL, Zhu TY, Wang BQ, Yu ZN, Jing L, Wu LM, Zheng SS, Sun JH

Received 14 January 2020

Accepted for publication 5 April 2020

Published 30 April 2020 Volume 2020:12 Pages 3023—3031

DOI https://doi.org/10.2147/CMAR.S245998

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Lu-Zhe Sun


Yue-Lin Zhang,1,2,* Tan-Yang Zhou,1,2,* Jing Ai,3,* Sheng-Qun Chen,1,2,* Feng Chen,4 Chun-Hui Nie,1,2 Xin-Hua Chen,1,2 Guan-Hui Zhou,1,2 Hong-Liang Wang,1,2 Tong-Yin Zhu,1,2 Bao-Quan Wang,1,2 Zi-Niu Yu,1,2 Li Jing,1,2 Li-Ming Wu,1,2 Shu-Sen Zheng,1,2 Jun-Hui Sun1,2

1Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, People’s Republic of China; 2Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou 310003, Zhejiang Province, People’s Republic of China; 3Eye Centre, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, People’s Republic of China; 4Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Jun-Hui Sun
Hepatobiliary and Pancreatic Interventional Treatment Center, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine; Zhejiang Clinical Research Center of Hepatobiliary and Pancreatic Diseases, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, People’s Republic of China
Tel +86 571 8723 6815
Email 1307005@zju.edu.cn
Feng Chen
Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, People’s Republic of China
Tel +86 571 8723 6815
Email chenfenghz@zju.edu.cn

Purpose: Gene-targeting therapy provides a novel therapeutic approach for tumor treatment using genetically modified endothelial progenitor cells (EPCs) as cellular carriers. This study applied EPCs armed with cytosine deaminase (CD) and endostatin (ES) fusion gene in liver cancer to explore its therapeutic effect.
Materials and Methods: EPCs from heart blood of male BALB/c nude mice were cultured and transfected with CD and ES fusion gene. Subsequently, these genetically modified cells were injected into mice bearing hepatoma through their tail veins. The tumor volumes and cell apoptosis were followed up.
Results: Tumor volume in the group injected CD/ES-EPCs greatly decreased. The positive rate of VEGF and CD31 in the tumor tissue was lowest in the CD/ES-EPC group. Furthermore, the number of apoptotic cells was highest in the CD/ES-EPC group.
Conclusion: The EPCs transfected with CD/ES inhibited tumor growth and preferentially induced tumor cell apoptosis, providing a novel methodology for cancer-targeting therapy.

Keywords: gene-targeting therapy, endothelial progenitor cell, endostatin, cytosine deaminase, hepatoma, transfection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]